Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts
What are the potential risks and uncertainties associated with the trial's statistical endpoints and patient enrollment timelines?
How will the new data influence analyst coverage, consensus estimates, and target price adjustments for TENX?
What potential partnership, licensing, or acquisition opportunities could arise from positive safety data and what are the market expectations for those deals?
21 days ago